The Fundamental Place of Pap Test in Iran, Does Primary HPV-Genotyping Seem Cost-Effective in Replace? A Cohort Study.

g, and more than half of the newly diagnosed cases are those who have not been screened.[ 3 , 4 , 5 , 6 , 7 ] Human papillomavirus (HPV) is the leading risk factor in developing nearly all cervical cancers, which infected near half of sexually active women.[ 8 , 9 ] According to the WHO statistics, an increasing trend of all cancers is predicted by 2040, especially in developing countries with low screening and diagnostic resources.[ 10 , 11 ] Although prior study revealed the low cost value for the implementation of national HPV vaccination in Iran, recent data seem controversial.[ 6 , 12 ] As a middle-income county, Iran falls in the category of countries with less than 30% coverage of HPV vaccination.

also in 63,971 other papers